A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

Investigational New Drugs

Volumn 26, Issue 2, 2008, Pages 193-194

  Knox, J J ^a   Chen, X E ^a   Feld, R ^a   Nematollahi, M ^a   Cheiken, R ^a   Pond, G ^a   Zwiebel, J A ^b   Gill, S ^c   Moore, M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Antisense oligonucleotide; Bcl 2; G3139; Hepatocellular carcinoma; Hepatoma; Phase I II

Indexed keywords

DOXORUBICIN; OBLIMERSEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TRANSAMINITIS; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 40549108674     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9104-1     Document Type: Article

References (12)

1. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer, an Eastern Cooperative Oncology Group trial. Cancer 54:970-977
2. Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1(8442):1006-1010
3. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1998) Doxorubicin versus no antitumour therapy in inoperable hepatocellular carcinoma: A prospective randomized trial. Cancer 62:479-483
4. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN (1993) Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4:327-332
5. Neuman MG (2001) Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci 38(2):109-166
6. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M (2005) Apoptosis in liver diseases-detection and therapeutic applications. Med Sci Monit 11:RA337-RA345
7. Chiu CT, Yeh TS, Hsu JS, Chen MF (2003) Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci 48(4):670-676
8. Cheng SC, Luo D, Xie Y (2001) Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol Int 25(3):261-265
9. Luo D, Cheng SC, Xie H, Xie Y (1999) Chemosensitivity of human HCC cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol 20(6):331-340
10. Ma S, Lee TK, Zheng BT, Chan KW (2007) CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (in press)
11. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD (2000) Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891-2902
12. Lopes de Menezes DE, Mayer LD (2001) Combination of bcl-2 antisense oligodeoxynucleotide (G3139), p-glycoprotein inhibitor (PSC833) and liposomal doxorubicin can suppress the growth of drug-resistant human breast cancer xenografts in SCID mice "abstract". Proc Ann Meet Am Assoc Cancer Res 42:A2018